TARGET IMMUNOTHERAPY IN SECONDARY IMMUNE DEFICIENCY WITH INFECTIOUS SYNDROME

  • Authors: Nesterova I.V.1,2
  • Affiliations:
    1. Federal State Budget Educational Institution of Higher Education «Kuban State Medical University» of the Ministry of Health Development of Russia
    2. Federal State Autonomous Budget Educational Institution of Higher Professional Education «Peoples’ Friendship University of Russia» of Ministry of Education and Science of Russia
  • Issue: Vol 22, No 4 (2019)
  • Pages: 1512-1516
  • Section: ORIGINAL ARTICLES
  • Submitted: 29.10.2020
  • Accepted: 29.10.2020
  • Published: 20.12.2019
  • URL: https://rusimmun.ru/jour/article/view/958
  • DOI: https://doi.org/10.31857/S102872210007074-6
  • ID: 958


Cite item

Full Text

Abstract

The main goal of this work is to highlight the current state of immunomodulatory therapy with targeted – targeted action, which is used effectively when conducting immunomodulatory therapy of secondary immunodeficiencies, provided that the immunomodulatory drug acts on a known receptor. For example, glucosaminylmuramipeptide acts through NOD2 or recombinant interferon alpha 2b with an antioxidant complex through the IFN alpha receptor. Modern data on targeted action drugs – monoclonal antibodies (monAT), currently used are given. The positive and negative effects of biologic therapy are described, as well as methods of preventing and preventing side effects. It has been suggested that in the future, in order to avoid errors and complications, monotherapy should be administered by clinical immunology (in collaboration with specialists from other fields of medicine) under the control of the immune system and interferon status.

About the authors

I. V. Nesterova

Federal State Budget Educational Institution of Higher Education «Kuban State Medical University» of the Ministry of Health Development of Russia;
Federal State Autonomous Budget Educational Institution of Higher Professional Education «Peoples’ Friendship University of Russia» of Ministry of Education and Science of Russia

Author for correspondence.
Email: fake@neicon.ru

Chief Researcher of Central Research Laboratory, Krasnodar;

Doctor of Medical Sciences (MD), Professor, Professor of the Department of Allergology and Immunology, Moscow

Russian Federation

References

  1. Нестерова И. В. Вторичные иммунодефициты и методы их коррекции в практике врачаоториноларинголога. «Иммунотерапия в практике ЛОР-врача и терапевта», под редакцией А. С. Симбирцева, Г. В. Лавреновой. Спб.: Диалог, 2018, 32–97.
  2. Нестерова И. В. Иммунотропные препараты и современная иммунотерапия в клинической иммунологии и медицине. Аллергология и иммунология, 2000, 23(3), 18–28.
  3. Tanaka T., Narazaki M., Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy, 2016, 8(8), 959–970.
  4. Van Ton A. M. P., Kox M., Abdo W. F., Pickkers P. Precision Immunotherapy for Sepsis. Frontiers In Immunology, 2018, https://doi.org/10.3389/fimmu.2018. 01926)).
  5. Castro M. G., Baker G. J., Lowenstein P. R. Blocking immunosuppressive checkpoints for glioma therapy: the more the merrier!. Clin Cancer Res., 2014, 20(20), 5147–5149.
  6. Kirkham B. W., Kavanaugh A., Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology, 2014, 141(2), 133–142. 7. Ballow M., Fleisher T. Secondary immunodeficiency induced by drugs and biologic therapies. UpToDate, 2015.https://www.uptodate.com/contents/secondaryimmunodeficiency-induced-by-biologic-therapies.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2019 Nesterova I.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № 77 - 11525 от 04.01.2002.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies